Macrophage Activation Syndrome (MAS) Market

Several investigational MAS therapies are currently progressing through clinical development, including ELA026 (Electra Therapeutics), Plonmarlimab (TJ Biopharma), Tadekinig alfa (AB2 Bio), MAS825 (Novartis), and additional candidates.

ELA026 from Electra Therapeutics is a first-in-class monoclonal antibody engineered to target Signal Regulatory Proteins (SIRPs) found on the surface of myeloid cells and T lymphocytes. By selectively depleting disease-driving immune cells, this novel mechanism holds therapeutic promise across multiple conditions.

Tadekinig alfa, developed by AB2 Bio, is a novel recombinant human interleukin-18 binding protein (IL-18BP) designed to neutralize IL-18 — a pivotal pro-inflammatory cytokine. Under normal physiological conditions, naturally occurring IL-18BP maintains free IL-18 at undetectable systemic levels. Tadekinig alfa is currently undergoing evaluation in a Phase III clinical trial.

In January 2025, AB2 Bio entered into an option and licensing agreement with Nippon Shinyaku covering US territories. Under the terms of this partnership, Nippon Shinyaku holds exclusive US commercialization rights for Tadekinig alfa in its primary indication — monogenic IL-18–driven hyperinflammatory syndrome associated with NLRC4 mutations and XIAP deficiency — spanning the US, Guam, Puerto Rico, and the US Virgin Islands. AB2 Bio retains rights for all other indications within these territories and for all indications in markets outside the US. The company continues to advance preparations for filing a US Biologics License Application (BLA) for Tadekinig alfa in this indication.

The expected market entry of these novel therapies is poised to reshape the MAS treatment landscape significantly. As these advanced candidates mature through development and secure regulatory approvals, they are expected to redefine standards of care while creating new avenues for clinical innovation and market expansion.

Discover more about the macrophage activation syndrome drugs @ Macrophage Activation Syndrome Drugs Market - https://www.delveinsight.com/report-store/macrophage-activation-syndrome-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Regional Competitive Landscape

1. Chugai Pharmaceutical Co., Ltd. (Japan)

• Drug candidate: Tocilizumab (Actemra/RoActemra)
• Phase(s): Phase III (in systemic JIA; MAS observed as outcome/adverse event)
• MOA: Anti–IL-6 receptor monoclonal antibody
• Clinical trial / registry:
• • Multiple global Phase III trials in systemic JIA (MAS captured as endpoint/adverse event; e.g., post-marketing surveillance in Japan)
• MAS relevance:
• • MAS occurs as a complication in treated patients; IL-6 blockade modifies cytokine signaling central to MAS pathophysiology
• Latest developments / data:
• • Real-world Japanese surveillance identified MAS cases (~5.8%) among treated patients
  • Tocilizumab is widely used in diseases associated with MAS (sJIA, AOSD)
• Notes:
• • While not a dedicated MAS trial sponsor, Chugai is one of the most important Japan-based contributors to MAS-relevant clinical data

2. Academic / Investigator-Sponsored (Japan; registry-linked but not company-led)

• Example registry:
• • NCT01095146 – MAS diagnostic criteria study
• Sponsor type: Academic consortia (Japan-based institutions)
• Relevance:
• • No direct pharma sponsor, but important for MAS clinical framework

3. Shionogi & Co., Ltd. (Japan)

• Direct MAS trials: None identified (as sponsor/co-sponsor)
• Relevance:
• • Active in immunology/infectious disease, but no MAS-specific pipeline or trials identified
• Conclusion:
• • Included for completeness; no evidence of MAS clinical-stage assets

4. Chong Kun Dang / CJ Bioscience / Other Korean pharmas

• Direct MAS-sponsored trials: None clearly identified
• Relevant activity:
• • Publications and case studies (e.g., tocilizumab-associated MAS cases in Korea)
• Conclusion:
• • Korean companies are not currently visible as sponsors of MAS interventional trials (Phase 1–3)

5. Celltrion (South Korea)

• Drug: Tocilizumab biosimilars (e.g., Avtozma)
• Phase: Biosimilar clinical development (Phase I–III equivalence studies)
• MOA: Anti–IL-6 receptor
• MAS relevance:
• • Indirect (same pathway as MAS cytokine storm biology)
• Regulatory update:
• • Biosimilars approved/launching globally (2024–2025 timeframe)
• Conclusion:
• • Indirect MAS relevance only

6. TWi Biotechnology / TaiGen / Others

• Direct MAS trials: None identified as sponsor/co-sponsor
• Conclusion:
• • No confirmed MAS-focused interventional trials

Recent Macrophage Activation Syndrome Market Developments

In October 2025, ELA026 was granted Breakthrough Therapy Designation (BTD) by the US FDA and received Priority Medicines (PRIME) designation from the European Medicines Agency for secondary HLH (sHLH).

In October 2025, Electra Therapeutics completed an oversubscribed USD 183 million Series C financing round. The round was co-led by Nextech and EQT Life Sciences, with participation from new investors Sanofi, HBM Healthcare Investments, and Mubadala Capital, alongside existing backers including OrbiMed, Redmile Group, New Leaf Venture Partners, Westlake BioPartners, Cormorant Asset Management, Blue Owl Capital, and RA Capital Management.

Understanding Macrophage Activation Syndrome

Macrophage activation syndrome (MAS) is a rare, severe, and potentially fatal hyperinflammatory condition defined by uncontrolled activation and expansion of macrophages and T lymphocytes, culminating in a cytokine storm. It most commonly arises in association with systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD), though it can also develop secondary to infections, malignancies, or other autoimmune and autoinflammatory conditions. MAS triggers excessive immune-mediated tissue destruction, presenting with hallmark clinical features including persistent high-grade fever, hepatosplenomegaly, cytopenias, hepatic dysfunction, coagulopathy, and markedly elevated inflammatory biomarkers — notably ferritin. Rapid clinical recognition coupled with aggressive immunosuppressive intervention is essential, as untreated MAS can swiftly progress to multi-organ failure.